542 related articles for article (PubMed ID: 20598649)
1. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
Glassman SD; Gum JL; Crawford CH; Shields CB; Carreon LY
Spine J; 2011 Jun; 11(6):522-6. PubMed ID: 20598649
[TBL] [Abstract][Full Text] [Related]
2. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
[TBL] [Abstract][Full Text] [Related]
3. Bone morphogenetic protein-2 used in spinal fusion with spinal cord injury penetrates intrathecally and elicits a functional signaling cascade.
Dmitriev AE; Farhang S; Lehman RA; Ling GS; Symes AJ
Spine J; 2010 Jan; 10(1):16-25. PubMed ID: 19914878
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
Dimar JR; Glassman SD; Burkus KJ; Carreon LY
Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers.
Glassman SD; Dimar JR; Burkus K; Hardacker JW; Pryor PW; Boden SD; Carreon LY
Spine (Phila Pa 1976); 2007 Jul; 32(15):1693-8. PubMed ID: 17621221
[TBL] [Abstract][Full Text] [Related]
6. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study.
Vaccaro AR; Whang PG; Patel T; Phillips FM; Anderson DG; Albert TJ; Hilibrand AS; Brower RS; Kurd MF; Appannagari A; Patel M; Fischgrund JS
Spine J; 2008; 8(3):457-65. PubMed ID: 17588821
[TBL] [Abstract][Full Text] [Related]
8. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
9. MOS short form 36 and Oswestry Disability Index outcomes in lumbar fusion: a multicenter experience.
Glassman S; Gornet MF; Branch C; Polly D; Peloza J; Schwender JD; Carreon L
Spine J; 2006; 6(1):21-6. PubMed ID: 16413443
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
11. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
12. Is it safe to use recombinant human bone morphogenetic protein in posterior cervical fusion?
Hiremath GK; Steinmetz MP; Krishnaney AA
Spine (Phila Pa 1976); 2009 Apr; 34(9):885-9. PubMed ID: 19531997
[TBL] [Abstract][Full Text] [Related]
13. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
14. Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases.
Glassman SD; Howard J; Dimar J; Sweet A; Wilson G; Carreon L
Spine (Phila Pa 1976); 2011 Oct; 36(22):1849-54. PubMed ID: 20838369
[TBL] [Abstract][Full Text] [Related]
15. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in older patients after posterolateral lumbar fusion.
Glassman SD; Carreon LY; Dimar JR; Campbell MJ; Puno RM; Johnson JR
Spine J; 2007; 7(5):547-51. PubMed ID: 17905316
[TBL] [Abstract][Full Text] [Related]
17. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
18. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study.
Carragee EJ; Mitsunaga KA; Hurwitz EL; Scuderi GJ
Spine J; 2011 Jun; 11(6):511-6. PubMed ID: 21612985
[TBL] [Abstract][Full Text] [Related]
19. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
Haid RW; Branch CL; Alexander JT; Burkus JK
Spine J; 2004; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of L5-S1 axial lumbar interbody fusion (AxiaLIF): a comparison with and without the use of recombinant human bone morphogenetic protein-2.
Gerszten PC; Tobler WD; Nasca RJ
Spine J; 2011 Nov; 11(11):1027-32. PubMed ID: 22122835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
